Clinicopathological and Molecular Characteristics of PIK3CA-mutant Gastric Cancer with Emphasis on its Tumor Immune Microenvironment

被引：0
|
作者：
Choi, Sangjoon [1 ]
Kim, Hyunjin [1 ]
Kang, Won Ki [1 ]
Kim, Kyoung-Mee [1 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
来源：
MODERN PATHOLOGY | 2022年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
401
引用
收藏
页码：436 / 438
页数：3
相关论文
共 50 条
  • [31] Classification based on intratumoral microbiome confer the molecular characteristics and immune microenvironment in gastric cancer
    Oh, Han Na
    Hur, Hoon
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [32] A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
    Donzelli, Sara
    Cioce, Mario
    Sacconi, Andrea
    Zanconato, Francesca
    Daralioti, Theodora
    Goeman, Frauke
    Orlandi, Giulia
    Di Martino, Simona
    Fazio, Vito Michele
    Alessandrini, Gabriele
    Telera, Stefano
    Carosi, Mariantonia
    Ciliberto, Gennaro
    Botti, Claudio
    Strano, Sabrina
    Piccolo, Stefano
    Blandino, Giovanni
    MOLECULAR CANCER, 2022, 21 (01)
  • [33] Lysine-Specific Demethylase 1 Mediates AKT Activity and Promotes Epithelial-to-Mesenchymal Transition in PIK3CA-Mutant Colorectal Cancer
    Miller, Samuel A.
    Policastro, Robert A.
    Savant, Sudha S.
    Sriramkumar, Shruthi
    Ding, Ning
    Lu, Xiaoyu
    Mohammad, Helai P.
    Cao, Sha
    Kalin, Jay H.
    Cole, Philip A.
    Zentner, Gabriel E.
    O'Hagan, Heather M.
    MOLECULAR CANCER RESEARCH, 2020, 18 (02) : 264 - 277
  • [34] AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition
    Rose, Madison M.
    Nassar, Kelsey W.
    Sharma, Vibha
    Schweppe, Rebecca E.
    MEDICAL ONCOLOGY, 2023, 40 (10)
  • [35] Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors
    Merino, Vanessa F.
    Cho, Soonweng
    Liang, Xiaohui
    Park, Sunju
    Jin, Kideok
    Chen, Qian
    Pan, Duojia
    Zahnow, Cynthia A.
    Rein, Alan R.
    Sukumar, Saraswati
    MOLECULAR ONCOLOGY, 2017, 11 (05): : 552 - 566
  • [36] Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
    Takahashi N.
    Yamada Y.
    Taniguchi H.
    Fukahori M.
    Sasaki Y.
    Shoji H.
    Honma Y.
    Iwasa S.
    Takashima A.
    Kato K.
    Hamaguchi T.
    Shimada Y.
    BMC Research Notes, 7 (1)
  • [37] Clinicopathological characteristics and prognostic analysis of PIK3CA mutation in breast cancer patients in Northwest China
    Lv, Wei
    Du, Chong
    Zhang, Yinbing
    Wu, Fei
    Jin, Yaofeng
    Chen, Xi
    Liu, Xuan
    Feng, Cong
    Ma, Xingcong
    Zhang, Shuqun
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 238
  • [38] Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer
    Yang, Wei
    Hosford, Sarah R.
    Dillon, Lloye M.
    Shee, Kevin
    Liu, Stephanie C.
    Bean, Jennifer R.
    Salphati, Laurent
    Pang, Jodie
    Zhang, Xiaolin
    Nannini, Michelle A.
    Demidenko, Eugene
    Bates, Darcy
    Lewis, Lionel D.
    Marotti, Jonathan D.
    Eastman, Alan R.
    Miller, Todd W.
    CLINICAL CANCER RESEARCH, 2016, 22 (09) : 2250 - 2260
  • [39] PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer
    Kim, Ji-Won
    Lee, Hye Seung
    Nam, Kyung Han
    Ahn, Soyeon
    Kim, Jin Won
    Ahn, Sang-Hoon
    Park, Do Joong
    Kim, Hyung-Ho
    Lee, Keun-Wook
    ONCOTARGET, 2017, 8 (53) : 90948 - 90958
  • [40] AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition
    Madison M. Rose
    Kelsey W. Nassar
    Vibha Sharma
    Rebecca E. Schweppe
    Medical Oncology, 40
12345